Medical devices, healthcare technology and the business of care
PMA approval · P240021

Atellica IM Total PSA II (tPSAII)

Siemens Healthcare Diagnostics, Inc. · Decision date Dec 3, 2025

FDA DECISIONP240021

What did the FDA approve?

FDA records P240021 as an original PMA application. The recorded decision is approval, dated Dec 3, 2025.

FDA approval order statement

Approval for the Atellica IM total PSA II (tPSAII):The Atellica IM total PSA II (tPSAII) assay is for in vitro diagnostic use in the quantitative measurement of total prostate-specific antigen (PSA) in human serum and plasma (EDTA and lithium-heparin) using the Atellica IM Analyzer. This assay is indicated as an aid in the detection of prostate cancer in conjunction with a digital rectal exam (DRE) in men aged 50 years and older. A prostate biopsy is required for the diagnosis of prostate cancer.
Regulatory pathway
Original PMA
Clinical specialty
Immunology
Decision date
Dec 3, 2025

FDA source record

Regulatory record facts

Identifier
P240021
Regulatory pathway
Premarket approval application
Product code
MTF
Decision code
APPR
Decision date
Dec 3, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Total, prostate specific antigen (noncomplexed & complexed) for detection of prostate cancer.

Product code
MTF
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P240021 received

    Application receipt date recorded by FDA.

  2. P240021 · FDA decision

    APPR

  3. P240021/S001 · Related supplement

    Atellica IM Total PSA II (tPSAII)

Timeline entries are records held by MedtechLedger for P240021. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P240021

Product / regulatory recordCompanyPathwayDecision dateSource
Siemens Healthcare Diagnostics, Inc.PMA supplementAug 26, 2026FDA

Explore the linked device profile

Other records with product code MTF

Product / regulatory recordCompanyPathwayDecision dateSource
Siemens Healthcare Diagnostics, Inc.PMA supplementSep 22, 2026FDA
Siemens Healthcare Diagnostics, Inc.PMA supplementAug 20, 2026FDA
IMMULITE 2000 PSAP930027/S039
Siemens Healthcare Diagnostics, Inc.PMA supplementJul 27, 2026FDA
Roche Diagnostics Corp.PMA supplementApr 29, 2026FDA
IMMULITE 2000 PSAP930027/S038
Siemens Healthcare Diagnostics, Inc.PMA supplementApr 21, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Siemens Healthcare Diagnostics, Inc.

Headquarters
Not reported
FDA applicant address
511 Benedict Ave., Tarrytown, NY, 10591

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records